Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Winsantor Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners, indicating that each pending application is being reviewed by a different official. The portfolio is also split between 2 distinct art units, which suggests that the company's biotechnological innovations fall into two separate technical categories. This distribution requires the company to manage two distinct prosecution tracks.
KOSAR, ANDREW D is identified as the busiest examiner, with 1 busiest examiner pending action. Given that there are 2 pending office actions in total, the workload is evenly divided between the 2 distinct examiners. This means the company must adapt to two different examination styles and sets of technical requirements. The 1 busiest examiner pending action shows that no single official has a majority share of the company's active cases.
The involvement of 2 distinct art units means the legal strategy must account for the specific practices of two different technical groups. With 2 pending office actions, the company's active workload at the patent office is focused but distributed. Practitioners should be prepared to handle unique feedback from each of the 2 distinct examiners. This profile reflects a targeted approach to securing intellectual property in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSAR, ANDREW D | 1 | 41.9% | +31.9% |
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17593792 | TOPICAL FORMULATIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | GONZALEZ, LUISALBERTO | 62d |
| 18767228 | COMPOSITIONS AND METHODS FOR IMPROVING SEXUAL SENSORY DISORDERS | KOSAR, ANDREW D | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18767228 | COMPOSITIONS AND METHODS FOR IMPROVING SEXUAL SENSORY DISORDERS | KOSAR, ANDREW D | 1625 | §103§112DP | Non-Final OA | — | Pending | Jul 09, 2024 |
| 17593792 | TOPICAL FORMULATIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | GONZALEZ, LUISALBERTO | 1624 | §103 | Final Rejection | 62d | Pending | Sep 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWinsantor Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Andrew D Kosar has the most, with 1 of Winsantor Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
